Plymouth Meeting, Pennsylvania headquartered Inovio Pharmaceuticals Inc.'s stock finished Monday's session at $8.33, jumping 6.52%. A total volume of 1.51 million shares was traded, which was above their three months average volume of 1.13 million shares. The Company's shares have gained 23.96% since the start of this year. The stock is trading below its 50-day moving average by 0.99%. Moreover, shares of Inovio Pharmaceuticals, which develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases, have a Relative Strength Index (RSI) of 60.80.
On November 07th, 2016, research firm Aegis Capital initiated a 'Buy' rating on the Company's stock.
On November 14th, 2016, Inovio Pharmaceuticals announced an interim data analysis showing that its INO-3112 cancer immunotherapy product generated antigen-specific CD8+ killer T cell responses measured both in tumor tissue and in peripheral blood from subjects with head and neck cancer associated with human papillomavirus (HPV). The immunology results show that INO-3112 treatment generated robust HPV16/18 specific CD8+ T cell responses in peripheral blood in four of five subjects who also showed increased T cell activation in resected tumor tissue samples. INO complete research report is just a click away and free at:
Pacific Biosciences of California
Shares in Menlo Park, California headquartered Pacific Biosciences of California Inc. ended yesterday's session 3.77% higher at $8.26 with a total trading volume of 853,797 shares. The stock is trading 3.08% below its 50-day moving average. Shares of the Company, which designs, develops, and manufactures sequencing systems to resolve genetically complex problems, have an RSI of 52.45.
On November 02nd, 2016, Pacific Biosciences of California announced that it has filed a complaint with the U.S. International Trade Commission against Oxford Nanopore Technologies Ltd and its affiliates. The complaint asserts that Oxford Nanopore's MinION and PromethION devices and associated consumables, reagents, and software, as well as related commercialization activities by Oxford Nanopore and its affiliates, infringe one or more claims of U.S. Patent No. 9,404,146 owned by Pacific Biosciences.
On November 03rd, 2016, research firm Cantor Fitzgerald reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $18 a share to $15 a share. The complimentary report on PACB can be downloaded at:
On Monday, Durham, North Carolina headquartered BioCryst Pharmaceuticals Inc.'s stock rose 6.37%, to close the day at $5.68. A total volume of 1.57 million shares was traded, which was higher than their three months average volume of 926,960 shares. The Company's shares have advanced 40.59% in the last one month and 29.98% in the previous three months. The stock is trading 28.14% above its 50-day moving average and 60.77% above its 200-day moving average. Additionally, shares of BioCryst Pharma, which designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases, have an RSI of 73.74.
On November 07th, 2016, BioCryst Pharma reported that for Q3 2016 revenues decreased to $7.8 million from $11.0 million in Q3 2015. Research and Development expenses for Q3 2016 decreased to $14.1 million from $20.1 million in Q3 2015. The net loss for Q3 2016 was $11.5 million, or a $0.16 net loss per share, compared to a net loss of $14.6 million, or $0.20 net loss per share, for Q3 2015. Sign up for your complimentary research report on BCRX at:
Shares in Richmond, California headquartered Sangamo Biosciences Inc. ended the day 2.25% higher at $4.55. A total volume of 932,825 shares was traded, which was above their three months average volume of 879,160 shares. The stock has gained 16.97% in the last one month and 1.11% in the previous three months. The Company's shares are trading above their 50-day moving average by 7.52%. Furthermore, shares of Sangamo Biosciences, which focuses on the research, development, and commercialization of engineered DNA-binding proteins for therapeutic genome editing and gene regulation, have an RSI of 62.86.
On November 01st, 2016, research firm Wedbush downgraded the Company's stock rating from 'Outperform' to 'Neutral'. The research firm also revised downwards its previous target price from $30 to $4. Get free access to your research report on SGMO at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA